Novo Nordisk On Target For 1996

18 August 1996

Novo Nordisk of Denmark has announced pretax profits of 1.2 billion Danish kroner ($209 million) in the first six months of 1996, an increase of 19%. Net income for the period was ahead 16% to 873 million kroner, and operating income was 1.1 billion kroner, up 8%. Earnings per share were 23.27 kroner, up 16%. The firm says its expectations for the full year are unchanged.

Consolidated sales for the company in the first half of 1996 amounted to 7 billion kroner, a rise of 2%. The sales increase for the continuing businesses, adjusted for business divestments, was 8%. Total licence fees and other operating revenues rose 12% to 202 million kroner. The major part of this income is attributed to licence fees from the antidepressant Seroxat/Paxil (paroxetine), which rose around 40%.

The group said that turnover measured in local currencies was as expected. However, currency movements reduced the increase measured in Danish kroner.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight